Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.47 EUR
Change Today +0.045 / 1.85%
Volume 0.0
As of 3:00 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

enzo biochem inc (EZB) Snapshot

Open
€2.51
Previous Close
€2.43
Day High
€2.51
Day Low
€2.43
52 Week High
09/9/14 - €4.66
52 Week Low
05/18/15 - €2.11
Market Cap
113.9M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
46.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENZO BIOCHEM INC (EZB)

enzo biochem inc (EZB) Related Businessweek News

No Related Businessweek News Found

enzo biochem inc (EZB) Details

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

433 Employees
Last Reported Date: 10/9/14
Founded in 1976

enzo biochem inc (EZB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $555.5K
Co-Founder, President, Chief Financial Office...
Total Annual Compensation: $492.7K
Senior Vice President of Finance
Total Annual Compensation: $123.8K
Vice President of Corporate Development
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

enzo biochem inc (EZB) Key Developments

Enzo Biochem Inc.(NYSE:ENZ) dropped from Russell 2000 Index

Enzo Biochem Inc. will be removed from Russell 2000 Index

Enzo Biochem Inc.(NYSE:ENZ) dropped from Russell 3000 Index

Enzo Biochem Inc. will be removed from Russell 3000 Index.

Enzo Biochem, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended April 30, 2015

Enzo Biochem Inc. announced unaudited earnings results for the third quarter and nine months ended April 30, 2015. For the quarter, the company reported total revenues of $23,986,000 against $23,978,000 a year ago. Loss before income taxes was $3,003,000 against $448,000 a year ago. Net loss was $2,907,000 against $455,000 a year ago. Basic and diluted loss per share was $0.06 against $0.01 a year ago. Non-GAAP net loss was $3,077,000 against $2,092,000 a year ago. Basic and diluted loss per share, non-GAAP was $0.07 against $0.05 a year ago. LBITDA was $2,010,000 against EBITDA of $601,000 a year ago. Adjusted LBITDA was $2,180,000 against $1,036,000 a year ago. Cash declined in the quarter by $1.0 million compared to the previous quarter ended in January, with approximately half that amount or $0.5 million invested in capital expenditures, including new lab equipment. For the first nine months, the company reported total revenues of $71,902,000 against $71,040,000 a year ago. Loss before income taxes was $10,815,000 against $6,743,000 a year ago. Net loss was $10,727,000 against $6,808,000 a year ago. Basic and diluted loss per share was $0.24 against $0.16 a year ago. Non-GAAP net loss was $10,897,000 against $8,475,000 a year ago. Basic and diluted loss per share, non-GAAP was $0.24 against $0.20 a year ago. LBITDA was $7,842,000 against $3,567,000 a year ago. Adjusted LBITDA was $8,012,000 against $5,234,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZB:GR €2.47 EUR +0.045

EZB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NanoString Technologies Inc $15.26 USD +0.82
NeoGenomics Inc $6.28 USD +0.30
Pacific Biosciences of California Inc $5.07 USD +0.21
Psychemedics Corp $11.10 USD +0.50
Sequenom Inc $2.23 USD +0.09
View Industry Companies
 

Industry Analysis

EZB

Industry Average

Valuation EZB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZO BIOCHEM INC, please visit www.enzo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.